Draped mantle of Roman citizens
POPULARITY
71 episodes with Toga
24 episodes with Toga
6 episodes with Toga
5 episodes with Toga
4 episodes with Toga
4 episodes with Toga
4 episodes with Toga
4 episodes with Toga
4 episodes with Toga
12 episodes with Toga
5 episodes with Toga
64 episodes with Toga
2 episodes with Toga
6 episodes with Toga
7 episodes with Toga
2 episodes with Toga
5 episodes with Toga
2 episodes with Toga
3 episodes with Toga
3 episodes with Toga
47 episodes with Toga
3 episodes with Toga
3 episodes with Toga
2 episodes with Toga
44 episodes with Toga
40 episodes with Toga
3 episodes with Toga
Prawnicy – nieomal wszyscy i od zawsze – boją się jednej rzeczy: że coś lub ktoś zabierze im pracę. Dziś patrzą w ten sposób na AI.Rozmawiam z Mateuszem Mulem i Mikołajem Więckiem, twórcami TuAsystenta – AI, które odbiera telefon zamiast Ciebie. Nie po to, żeby doradzać klientom zamiast prawnika. Po to, żeby przefiltrować połączenia, które i tak nie wymagały Twojej głowy, tylko Twojego czasu.Ten odcinek jest o tym, co się dzieje, kiedy telefon przestaje rządzić Twoim dniem.W środku między innymi:– dlaczego prawnicy boją się AI dokładnie tak, jakby bali się kserokopiarki, że odbierze im pracę– co się dzieje z tajemnicą zawodową i danymi osobowymi, kiedy w grę wchodzi asystent głosowy– różnicę między tym, co AI może zrobić za Ciebie, a tym, za co klient tak naprawdę płaci prawnikowi– jak wygląda rozmowa telefoniczna prowadzona przez asystenta krok po kroku, łącznie z tym, czego prawnik NIE dostaje– co się dzieje z klientami, którzy dzwonią po godzinach pracy kancelarii– historię sprawy za 40 tysięcy złotych, którą uratował jeden SMS wysłany z sali rozpraw– dlaczego czasem najlepszy prawnik to ten, który nie odbiera telefonu– dlaczego twórca rozwiązania AI mówi wprost: „umowy spółki sam bym sobie nie napisał”Odcinek dla adwokatów, radców prawnych, doradców podatkowych, rzeczników patentowych i wszystkich, którzy zarządzają kancelarią lub zespołem prawnym i czują, że telefon rządzi ich dniem zamiast oni nim.TuAsystenta znajdziesz i przetestujesz pod adresem: https://tuasystent.plMożesz go również zaobserwować w mediach społecznościowych:YT: https://www.youtube.com/@TuAsystentIG: https://www.instagram.com/tuasystent.pl/LinkedIn: https://pl.linkedin.com/showcase/tuasystent-pl/Sponsorem i partnerem aktualnego sezonu podcastu Toga bez wroga jest move2edge Sp. z o.o., producent asystenta AI dla kancelarii prawnych TuAsystent.pl–––Nieodpłatna superwizja grupowa dla prawników – https://togabezwroga.pl/superwizja–––Podcast „Toga bez wroga” jest częścią projektu Zagubione Perły Fundacji Alchemia Zmiany, którego celem jest dobrostan człowieka, jego zrównoważony rozwój oraz rozwój przedsiębiorczości.#współpraca #płatnawspółpraca
Choice Classic Radio presents Sherlock Holmes, featuring today's episode titled “The Cadaver in the Roman Toga.” Please consider supporting our show by becoming a patron at http://choiceclassicradio.com We hope you enjoy the show!
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Steven Kao, Medical Oncologist at Chris O'Brien Lifehouse, is joined by A/Prof Venessa Chin, Medical Oncologist at St Vincent's Hospital and Researcher at the Garvan Institute of Medical Research, and Dr Ben Kong, Medical Oncologist at Prince of Wales Hospital. Together, they explore the clinical features of ROS1-positive non-small cell lung cancer, the evolving diagnostic and treatment landscape in Australia, and how the recent PBS listing of repotrectinib is influencing first-line treatment decisions. The discussion also covers CNS disease, treatment sequencing, resistance mechanisms, and emerging therapies that may further improve outcomes for patients. This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Introduction, Host Welcome & Acknowledgement of Country (01:33) The "Unicorn" Mutation: Clinical Characteristics & Prevalence (03:22) Diagnostic Testing: IHC, FISH vs. Gold Standard NGS (05:15) Clinical Red Flags: High Thromboembolic Risk & CNS Predilection (08:18) Treatment Landscape in Australia: Crizotinib, Entrectinib, Repotrectinib (10:11) Managing Unique Repotrectinib Side Effects (Dizziness, Dysgeusia, Ataxia) (13:42) Intracranial Response & Choosing First-Line TKIs (19:20) Post-TKI Progression Strategies: Biopsy, Chemo-IO, & Local Stereotactic Radiotherapy (SRS) (26:15) The Horizon: Emerging Next-Generation TKIs & Resected ROS1 Disease (29:05) Closing Remarks ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Mel Moore welcomes Prof Zarnie Lwin OAM (University of Queensland; Medical Oncologist at Royal Brisbane and Women's Hospital and The Prince Charles Hospital) to discuss her pathway from Burma to training in South Africa and Australia, and a two-year lung cancer fellowship at Princess Margaret Cancer Centre in Toronto. Prof Lwin reflects on choosing medical oncology, the value of leaving one's institution for fellowships, and how international training shaped her professionalism, networks, and research direction. She explains health services and qualitative research, highlighting a project interviewing interpreters that revealed cultural and language gaps around cancer and palliative care. The episode also covers equity-focused solutions (community and clinician education, in-person interpreters, cultural competency, and potential AI tools), challenges to clinical trial recruitment due to increasingly niche criteria and geographic distance, limited experience with teletrials, and her commitment to mentorship and humility in a rapidly evolving lung cancer field. 00:00 Welcome and Acknowledgement 00:37 Meet Professor Lwin 04:25 Training Across Countries 07:19 Choosing Medical Oncology 08:34 Medicine and Creativity 11:56 Fellowship Advice and Mentors 16:42 Health Services Research 19:06 Interpreters and Culture 25:40 Clinical Trial Barriers 30:43 Teletrials and Equity 32:29 Mentorship and Teaching 35:24 Episode Wrap Up ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
Spajanje odmora na Jadranu i dobre zabave pokazalo se kao dobitna kombinacija. Toga su svjesni i u Puli. U tamošnjoj Areni ovog ljeta nastupalo je mnogo zvijezda svjetske scene, među njima i Nick Cave & The Bad Seeds. A što je ostatkom godine? Nenad Kreizer o svemu tome razgovara s pulskim gradskim vijećnikom Goranom Mihovilovićem. Uroš Milovanović nam u pregledu srpske glazbene scene predstavlja nekoliko novih imena. Slušamo i nove singlove bandova Duper ("Pretera") Vizelj ("Neću biti sam"). Von Nenad Kreizer.
Join Captain Jeff, Captain Nick, Captain Steffen, and Producer Liz. Enjoy! APG 720 SHOW NOTES WITH LINKS AND PICS 00:00:00 Introduction 00:06:13 NEWS 00:06:30 Vietnam B789 Late Rotation, Tailstrike, Runway Overrun 00:39:33 Lufthansa A380-800 Touched Down Short of Runway 00:46:23 Two Aircraft Same Callsign 01:03:25 Small Plane Collides with Pennsylvania State Police Helicopter 01:14:39 GETTING TO KNOW US 01:45:25 FEEDBACK 01:45:39 Coyote vs. Acme 01:47:30 Jim Fulton – Boeing 777-200F Freighter Prestwick to Melbourne Flight 01:53:00 MetroDoc – Controller Gets Angry with Impatient Pilots | LaGuardia Vibes? 02:00:19 WRAP UP Watch the video of our live stream recording! Go to our YouTube channel! Give us your review in iTunes! I’m “airlinepilotguy” on Facebook, and “airlinepilotguy” on Twitter. feedback@airlinepilotguy.com airlinepilotguy.com ATC audio from https://LiveATC.net Intro/outro Music, Coffee Fund theme music by Geoff Smith thegeoffsmith.com Dr. Steph’s intro music by Nevil Bounds Capt Nick’s intro music by Kevin from Norway (aka Kevski) Copyright © AirlinePilotGuy 2026, All Rights Reserved Airline Pilot Guy Show by Jeff Nielsen is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer. The conversation explores how social constructs and industry blame-shifting fuel psychological distress, create barriers to the National Lung Cancer Screening Program, and potentially compromise equitable patient care. The panel offers clinical, psychological, and biological perspectives on how the healthcare system can dismantle this stigma to improve patient outcomes and quality of life. Host A/Prof Gavin Wright is a thoracic surgeon, director of Surgical Oncology at St. Vincent's Hospital, and the surgical representative on TOGA's scientific committee—is an esteemed panel of specialists leading the charge against lung cancer stigma. He is joined by Dr. Allison Black, an oncology consultant at the Royal Hobart Hospital who sub-specialises in gynecological and lung cancers; A/Prof Henry Marshall, a thoracic physician at the Prince Charles Hospital and the University of Queensland Thoracic Research Center; and Professor Suzanne Chambers, a health psychologist, psycho-oncology researcher, and Executive Dean of Health Sciences at the Australian Catholic University. Together, they bring a vital combination of surgical, oncological, respiratory, and psychological expertise to this crucial discussion. 00:00 Welcome and Acknowledgement 00:55 Meet the Panel 01:54 What Stigma Means 04:43 Tobacco Industry Blame 06:11 Why Screening Matters 08:44 Treatment Without Judgment 12:15 Fixing Stigma Systemwide 17:13 Equity and Access Gaps 18:35 Shared Decisions and Support 21:24 Quitting Without Shame 24:33 Language and Closing Takeaways 26:49 Episode Wrap Up ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
O governador de Minas Gerais, Mateus Simões, voltou a criticar o Supremo Tribunal Federal, afirmando que a Corte atua com "justiça de mão própria".A declaração do chefe do Executivo mineiro ocorre no contexto da repercussão do caso do jornalista afetado por medidas de quebra de sigilo de fontes autorizadas em investigações no Supremo.Papo Antagonista é o programa que explica e debate os principais acontecimentos do dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores. O programa traz contexto e opinião sobre os temas mais quentes da atualidade. Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade.
A decisão de Alexandre de Moraes contra a fonte do jornalista Luís Pablo provoca forte reação política.Direto do Salão Verde da Câmara, Wilson Lima entrevista o deputado Capitão Alberto Neto (PL-AM), que classifica a medida como "ditadura da toga" e projeta uma bancada de oposição capaz de abrir um processo de impeachment de ministro do STF após 2026.O Meio-Dia em Brasília também traz a nota de defesa do ministro Flávio Dino, que nega uso irregular de veículo oficial, e o fechamento de Wilson Lima e Ricardo Kertzman sobre por que a quebra do sigilo abre um precedente grave para a democracia.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto de Brasília. Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil. Com um olhar atento sobre política, notícias e economia, mantém o público bem informado. Transmissão ao vivo de segunda a sexta-feira às 12h no nosso canal do Youtube. https://www.youtube.com/@OAntagonista Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay: https://assine.oantagonista.com.br/ Siga O Antagonista no X: https://x.com/o_antagonista Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais. https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344 Inscreva-se no canal, ative as notificações e deixe sua opinião nos comentários! Leia mais em www.oantagonista.com.br | www.crusoe.com.br #Spotify #ApplePodcasts #AmazonMusic #TuneInRádio #PapoAntagonista #PolíticaBrasileira #BastidoresDoPoder #economia #jornalismo #oposicao #reacao #moraes #stf #toga #tirania #congresso #senado #deputados #protesto #discurso #politica #brasil #debate #podcast #noticia #critica #republica #declaracao #atualidade
After dropping 5minutes off her personal best in Boston, Maryann Gong is shooting for an OTQ in Chicago.With a 2:38 marathon PB she is right on the cusp of qualifying for the Olympic Trials. She takes us through her training, mindset, and prep for her OTQ attempt at Chicago.She also shares about her injury history and her decision to get surgery on her Haglunds Deformity. She is also a founder of a run coaching app called Toga. Toga is a personalized run training app for serious runners who are chasing PRs while balancing a busy life. It builds you a custom plan tailored to your goals and history with running, strength and prehab that adapts based on your real workouts, schedule and life. Whether you're looking for a full coach or just a copilot, Toga can help you reach your goals. Syncs with Garmin, Coros, Apple Health, Strava, and more. Available on iOS.: https://apps.apple.com/app/apple-store/id6758282443?pt=128052523&ct=d3glorydays&mt=8Follow her on Insta for more updates: https://www.instagram.com/maryanngong/Tailwind Nutrition is sponsoring today's episode. Whatever your training looks like turn to Tailwind to fuel you.Complete Nutrition Made Simple - Tailwind offers easy-to-digest, all-in-one fueling, recovery, and hydration for endurance athletes. Made for Athletes, by Athletes - Born out of real experience on the trails and refined with customer feedback. Get 20% off your first order when you used code GloryDays20 at tailwindnutrition.com/GLORYDAYSBoulderthonAre you looking for your next race? You hear Noah talk about how much he loves running in Boulder and now's your chance to see why he loves it so much. is Boulder, CO's signature downtown marathon series taking place on September 27, 2026!Boulderthon has it all. From the 5k to the marathon, there is a race for everyone. Believe you can and you will!Boulderthon is offering $20 off to our readers for the Half or Marathon. Use code D3GloryDays at boulderton.orgHow to Support D3 Glory Days:THE NEWSLETTER!D3 Glory Days Venmo.We launched a Patreon!Subscribe and leave us a review on Apple PodcastsInstagram,Twitter and Strava.
Kalau makan enak kalian biasanya ke mana atau makan apa? Kalau saran saya sih, Ali You Can Eat! Pasti kenyang dengan jokes-jokes lucu dari komika satu ini. Ali Akbar, sudah menjadi tamu di podcast Helmy Yahya Bicara! Simak selengkapnya, dijamin grrrrrrrr terussss!
O se meaalofa i se malae taalo basketball,soka ma se suigi ma faasee na faimeaalofa atu ai le Terry Campese Foundation mo le aoga tulaga lua a Asau.E le gata i lea o ni laptops e 20 mo mataupu suesue a le fanau ma sa vaaia le talia ma le agaga faafetai e le Aoga.O lenei fesoasoani faifua e Terry Campese na malaga atu ai i Toga ma Papua ae o lea ua manuia ai ma Samoa.Saunoa Terry Campese e faia i tausaga uma lenei galuega fesoasoani ma e aoga tele mo tamaiti e 41 na o latou malaga atu mai Ausetalia.Mo nisi tala maoae o fesoasoani faapenei ma tala mai Samoa ma atunuu mamao.Faafofoga mai i le SBS Samoan i Aso Lulu 2pm ma Aso Faraile 2pm i vaiaso taitasi
In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Mel Moore interviews Dr. Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery, and specialising in minimally invasive thoracic surgery and pleural disease. Dr. Eckhaus discusses her extensive training and experience, groundbreaking work in robotic lung surgery, and her contributions to the development of the Binational Australian and New Zealand Thoracic Surgical Database. The conversation also explores Dr. Eckhaus' academic pursuits in clinical ethics at Oxford University and the practical implications for informed consent in surgical procedures. This episode provides an in-depth look into the evolving field of thoracic surgery, advancements in robotic technology, and the essential role of comprehensive data collection in improving patient outcomes. (00:00) Introduction and Acknowledgements (00:39) Meet Dr. Jazmin Eckhaus (01:52) Journey to Thoracic Surgery (04:57) Robotic Surgery Innovations (11:53) Thoracic Surgical Database (15:53) Clinical Ethics and Consent (26:19) Personal Interests and Conclusion Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
The Professor brings The Dean back into the Down & Dirty chaos for a host-led episode full of pool party rules, toga-party opinions, potluck crimes, celebrity hall-pass games, and one very important warning: if you are lucky enough to get invited to a lifestyle pool party, dry your ass off before walking inside. From vasectomy follow-up comedy and “jerking off should be easier” business ideas to WhiteChocolate sexy, gods-and-goddesses themes, house-party etiquette, spicy jerk chicken, fruit salad standards, and Down & Dirty's version of marry/fuck/kill, this episode is loose, ridiculous, and very much built for the listeners who love the crew when they are just talking shit. In This Episode: The Professor's vasectomy follow-up story takes an unexpected turn The Dean returns to the podcast Toga parties, gods-and-goddesses themes, and WhiteChocolate sexy Pool party rules and why wet people almost ruined everything The Dean's naughty list Why house-party guests need to bring better food Potluck crimes, fruit salad standards, and spicy jerk chicken The Prince helping run his first pool party Down & Dirty's version of marry/fuck/kill Why the credits might be worth listening to Guests & Credits: Hosts — The Professor and The Dean Producer — David Produced by — Down & Dirty Productions Company Music — Victoria Sponsored by: Glitz by Jax — Custom body art and glitter for dazzling nights Passionscapes Photography — Photography and creative support CouplesNextDoor.com — Studio sponsor and lifestyle community network CND New Member Promo Code: Use code DD25 when signing up to support the show.
In this second part of TOGA's Conversations in Lung Cancer Research two-episode series, A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital, leads a panel discussing the clinical implications of the March 1st broad Pharmaceutical Benefits Scheme (PBS) listing of ipilimumab and nivolumab in Australia. Joined by Prof Nick Pavlakis (Senior Staff Specialist at Royal North Shore Hospital, Professor of Medicine at the University of Sydney, former chair of TOGA), Dr. Sam Bowyer (Medical Oncologist at Sir Charles Gairdner Hospital and Clinical Researcher at Linear Clinical Research) and Dr. Lavinia Tan (Medical Oncologist at Peter MacCallum Cancer Centre), the conversation explores how this newly granted flexibility alters treatment paradigms across various thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, small cell lung cancer (SCLC), and rare thymic tumours while also addressing toxicity management and the growing demands of patient survivorship. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Welcome and Acknowledgement (01:33) Panel Introductions (02:52) First Reactions in Clinic (05:01) Frontline NSCLC Evidence (06:48) Who Gets Ipi Nivo? (11:29) Chemo Free and Rechallenge (15:20) Stopping or Continuing IO (20:34) Mesothelioma Treatment Choices (27:20) Small Cell Reality Check (30:21) Thymic Malignancies Debate (34:54) Governance and Toxicity Safety (38:44) Survivorship and Follow Up (43:43) Real World Data Next Steps (48:05) Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
#influencias #jueces #supremo El tracto del caso de un abogado contra un empresario ponceño al que probó que cometió fraude en su cintra en un contrato de negocios, trae información de cómo se organizan pleitos civiles que trajo dos Ex Jueces Supremo se que cuando llevaron la Toga tomaron decisiones sobre el caso. Hoy revelamos la trama de influencias en el caso de Ramon Cacho Pérez contra Robert Hatton, lo que puede convertirse en un caso ético contra los ex Jueces, Federico Hernández Denton y Edgardo Rivera García. La imputación en un pleito que data ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo Síguenos en nuestras redes sociales: tiktok.com: https://x.com/Bonita_Radio Facebook: / bonitaradio Instagram: / bonitaradio X: https://x.com/Bonita_Radio
#influencias #jueces #supremo El tracto del caso de un abogado contra un empresario ponceño al que probó que cometió fraude en su cintra en un contrato de negocios, trae información de cómo se organizan pleitos civiles que trajo dos Ex Jueces Supremo se que cuando llevaron la Toga tomaron decisiones sobre el caso. Hoy revelamos la trama de influencias en el caso de Ramon Cacho Pérez contra Robert Hatton, lo que puede convertirse en un caso ético contra los ex Jueces, Federico Hernández Denton y Edgardo Rivera García. La imputación en un pleito que data ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo Síguenos en nuestras redes sociales: tiktok.com: https://x.com/Bonita_Radio Facebook: / bonitaradio Instagram: / bonitaradio X: https://x.com/Bonita_Radio
In this first part of a special two-episode series of TOGA's Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O'Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide. The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of 'once in a life time' rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient's individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. Resource Links: CM816 https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 CM9LA https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/abstract CM227-https://www.nejm.org/doi/full/10.1056/NEJMoa1910231 CM227 was a clinical trial that examined ipi/nivo, nivo alone or chemotherapy in pts with NSCLC with PD-L1 expression level of 1% (00:00) Welcome and Acknowledgement (02:00) New PBS Listing Explained (04:18) Defining Advanced and Sensitive (07:18) Dual vs Single Immunotherapy (12:27) Early Stage and Recurrence (14:26) Duration Stopping and Restarting (20:57) Other Thoracic Cancers (23:55) System Impact and Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
Twee beursdagen verder en het is gelijk raak. SpaceX doet een gigantische overname. 60 miljard dollar is ermee gemoeid. Het neemt Anysphere over, een softwarebedrijf vooral bekend van hun AI-model Cursor. Dat is dan vooral weer bekend onder 'vibecoders': mensen die AI gebruiken om te coderen. We zoeken uit of de kersverse SpaceX-aandeelhouders blij moeten zijn met deze nieuwe aanwinst. We kijken wat Cursor precies kan toevoegen aan het ruimtevaartbedrijf. Of moeten we het ondertussen gewoon een AI-bedrijf gaan noemen? En je hoort hoe lang het aandeel van SpaceX de spectaculaire stijging nog kan doorzetten. Verder hebben we het ook over concurrent OpenAI. Ook daar weten ze maar al te goed wat uitgeven is. Er gaat ongeveer drie keer zoveel geld per jaar uit als dat er binnenkomt. En er vloeien ook miljarden naar marketing. Kan het toekomstige beursbedrijf hun toekomstige aandeelhouders met dat soort cijfers wel overtuigen dat ze ooit winstgevend gaan zijn? We vertellen je ook nog over Box 3. De nieuwe wet kreeg al bakken met kritiek maar dat blijkt nog niet genoeg. Tweede Kamerpartijen hopen de wet voor de zomer nog van tafel te krijgen. Te gast: Robbert Manders van het Antaurus Europe Fund BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.
Twee beursdagen verder en het is gelijk raak. SpaceX doet een gigantische overname. 60 miljard dollar is ermee gemoeid. Het neemt Anysphere over, een softwarebedrijf vooral bekend van hun AI-model Cursor. Dat is dan vooral weer bekend onder 'vibecoders': mensen die AI gebruiken om te coderen. We zoeken uit of de kersverse SpaceX-aandeelhouders blij moeten zijn met deze nieuwe aanwinst. We kijken wat Cursor precies kan toevoegen aan het ruimtevaartbedrijf. Of moeten we het ondertussen gewoon een AI-bedrijf gaan noemen? En je hoort hoe lang het aandeel van SpaceX de spectaculaire stijging nog kan doorzetten. Verder hebben we het ook over concurrent OpenAI. Ook daar weten ze maar al te goed wat uitgeven is. Er gaat ongeveer drie keer zoveel geld per jaar uit als dat er binnenkomt. En er vloeien ook miljarden naar marketing. Kan het toekomstige beursbedrijf hun toekomstige aandeelhouders met dat soort cijfers wel overtuigen dat ze ooit winstgevend gaan zijn? We vertellen je ook nog over Box 3. De nieuwe wet kreeg al bakken met kritiek maar dat blijkt nog niet genoeg. Tweede Kamerpartijen hopen de wet voor de zomer nog van tafel te krijgen. Te gast: Robbert Manders van het Antaurus Europe Fund BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.
Rob and MJ talked all things Belmont with Matthew DeSantis from NYRA Bets!
Rob and MJ talked all things Belmont with Saratoga County Chamber of Commerce President Todd Shimkus!
Rob and MJ talked again with the great Andy Serling from NYRA and FOX Sports!
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide, leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer. Joined by Prof Ahn Myung-ju, a Medical Oncologist at Hanyang University Medical Centre in South Korea as well as Co-chair for the upcoming World Lung Cancer Conference, and A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital in Sydney. The panel discusses the clinical characteristics and incidence of this molecular subset, the critical need for upfront comprehensive genomic testing, key clinical trial data for targeted therapies, and practical strategies for managing treatment-specific side effects like pyrexia syndrome. This episode is sponsored by Pierre Fabre. (00:00) Welcome and Acknowledgement (00:47) Introducing the Topic and Panel (01:56) BRAF Incidence Overview (02:43) Testing Pathways in Australia (06:16) Mutation Classes and Tools (07:47) Korea Testing Perspective (09:03) Pivotal Targeted Therapy Trials (13:33) Choosing First Line Treatment (16:40) Australian Sequencing Approach (20:23) Managing Pyrexia and Toxicities (25:49) Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
The crew is back for episode 131 and TY opens the show by declaring war on Luka Doncic (yes, really). From there it's a packed one: the Obsession horror movie spoiler breakdown, the NBA Finals matchup between the Knicks and Spurs, Sony's State of Play, the new God of War reveal, plus heavy anime discussion across Blue Lock, Witch Hat Atelier, Daemons of the Shadow Realm, and Re:Zero Season 3.SPOILER ZONE: Obsession (2026) full breakdown starts early. Skip ahead if you haven't seen it.What we get into:Naming the craziest female anime villains better than Nikki from Obsession (Yuno Gasai, Shiro from Deadman Wonderland, the full Kakegurui lineup, Toga, Makima, Priscilla, and more)Is Nikki actually the villain of Obsession, or is Bear the real problem? The Ian debate gets heatedSarah's death scene, the diner moment, the One Wish Willow rules, and that ending sequenceBest horror performances of the 21st century: Toni Collette, Bill Skarsgård, Lupita Nyong'o, William Dafoe, James McAvoy, and Andy Navarro's case for the listHorror Movie King of the Hill: Obsession vs Get Out, Hereditary, Midsommar, Insidious, Conjuring, Sinners, Paranormal Activity, and Talk to MeWishes the crew would make to fix anime: Reborn pacing, Gintama actually being funny, Promised Neverland Season 2 erased, Future Trunks staying in the main timeline, the Black Clover finale Asta vs Yuno fight, and Berserk going to MAPPABlue Lock chapter reactions: is Ego's philosophy actually wrong? The Isagi vs Hugo aftermath and what comes nextWitch Hat Atelier: Kifri going too far, the Brimcap mystery, Coco and Tartar's growing dynamic, plus a real talk comparison between magic gatekeeping and AI regulationDaemons of the Shadow Realm: who's the Kagamori traitor (Bald Guy slander incoming), Yuru's future, and the grandma agendaRe:Zero Season 3: amnesia Subaru crash out hype, the staircase scene anticipationNBA Finals predictions: Knicks vs Spurs, the Cat factor, how Brunson handles Stephon Castle and Dylan Harper, and whether NYC actually wilds out if the Knicks winNFL chaos: Rams trading for Myles Garrett (Aaron Donald comeback talk), Patriots landing AJ Brown, and which playoff teams are dropping out next seasonSony State of Play reactions: Marvel's Wolverine, Onimusha, Tomb Raider, and the new God of War starring Kratos' wife (DLC energy or worth the slot?)Wuthering Heights debate: Margot Robbie's performance and Radell holds the line on his original takePlus, the crew is two episodes deep on the Game of Thrones Season 8 Patreon rewatch, House of the Dragon Season 3 watch party prep, and a Mask vs Mask WWE match getting flowers.If you mess with anime debates, horror movie takes, NBA discourse, and gaming reactions all in one place, lock in.KEYWORDS (SEO-loaded for podcast platforms and YouTube):Black Sensei Society, BSS podcast, anime podcast, Obsession movie review, Obsession 2026 spoilers, Andy Navarro Obsession, best horror movies of 2026, horror movie king of the hill, best horror performances 21st century, Yuno Gasai, Kakegurui, Makima, anime villainess tier list, Blue Lock chapter review, Ego philosophy Blue Lock, Isagi vs Hugo, Witch Hat Atelier review, Kifri Coco Tartar, Daemons of the Shadow Realm, Re:Zero Season 3, Subaru amnesia arc, NBA Finals 2026, Knicks vs Spurs prediction, Jalen Brunson, Victor Wembanyama, Stephon Castle, Karl Anthony Towns, Myles Garrett trade, Rams Super Bowl, Patriots AJ Brown, Sony State of Play, Marvel's Wolverine, new God of War 2027, Kratos wife game, Onimusha Way of the Sword, Tomb Raider, Wuthering Heights Margot Robbie, anime debate podcast, manga podcast, sports and anime podcast, Black podcastershttps://linktr.ee/blacksenseisociety
On this edition of the podcast Eric is joined by Houston BBQ Festival co-founder Michael Fulmer. Since the news edition of the podcast has been off for a couple of weeks, the duo catch up on some of the biggest news from the Houston culinary scene including Betelgeuse Betelgeuse owner Chris Cusack getting arrested for health code violations, Mack McDonald getting set to open a new steakhouse concept, and Bludorn Hospitality's latest endeavor - a mystery concept in San Antonio. In the Restaurants of the Week portion, Toga and Sip & Skewer are featured.Got a question for Eric? Email him at eric@culturemap.com. Follow Eric on Instagram @ericsandler and check out some of Eric's latest articles online at Culturemap.com: Houston Bar Owner Speaks Out About Surprise Arrest for Health Code Violations Houston Restaurateur Steps Up with Massive River Oaks-Area Steakhouse Texas Comfort Food Restaurant Closes at Memorial City After 10 Years Chris Shepherd's TV Show Eat Like a Local Ends its Run After 3 Years Croissant-Obsessed French Cafe Sets Opening Date in Downtown Houston Park
Ovaj video objašnjava kako tvoja slika o sebi oblikuje sve što doživljavaš u životu i zašto se pravi napredak počinje tek kada promijeniš način na koji vidiš sebe.
Solve crimes with the great detective in "Sherlock Holmes Short Stories." Featuring classic tales by Arthur Conan Doyle, this podcast brings you the brilliant deductions and thrilling adventures of Sherlock Holmes and Dr. Watson. Whether you're a longtime fan or new to the world of Holmes, these timeless mysteries will keep you captivated.
Spurs Chat: Discussing all Things Tottenham Hotspur: Hosted by Chris Cowlin: The Daily Tottenham/Spurs Podcast Hosted on Acast. See acast.com/privacy for more information.
Existe um momento em que a justiça deixa de ser princípio… e vira ritual. Neste episódio, partindo da queda de Harvey Dent em The Dark Knight, mergulhamos numa pergunta incômoda: o que acontece quando quem julga abandona o critério e passa a decidir por narrativa, convicção ou conveniência? Sem caricaturas, exploramos as lentes que moldam decisões sob poder, do cinismo ao fanatismo, da vaidade à desumanização, para entender onde termina a lei… e começa o homem por trás da toga. See omnystudio.com/listener for privacy information.
Der Release des großen Vulkan-DLCs für Anno 117 ist geplatzt! Ubisoft zog in allerletzter Sekunde die Notbremse, denn ein kritischer Bug drohte, unsere hunderte Stunden alten Savegames zu zerstören. Zusammen mit Strategie-Experte Writing Bull atmen wir kurz auf, denn die Verschiebung war die absolut richtige Entscheidung. Doch danach machen wir den großen Reality-Check ohne rosarote Brille: Wo steht Anno 117 knapp ein halbes Jahr nach Release wirklich? Wir diskutieren über Ubisofts kurioses Planungs-Chaos (Hallo, Heroes of Might & Magic!), den dringend nötigen Nerf des übermächtigen Passivhandels mit Update 1.5 und klären die wichtigste Frage: Ist das Aufbau-Epos jetzt endlich in dem Zustand, den wir uns gewünscht haben? Schnappt euch eure Toga, lehnt euch zurück und diskutiert mit: Seid ihr froh über die Notbremse oder einfach nur genervt vom Hin und Her? Alle Links zum GameStar Podcast und unseren Werbepartnern: https://linktr.ee/gamestarpodcast
Editorial: Escravos de toga
The_Cadaver_in_the_Roman_Toga
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including: A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA Key ongoing trials of HER2-directed therapies in BTC and GEA Presenters: Amit Mahipal, MD, MPH Chief, GI Medical Oncology Program Professor of Medicine Ruth and Goodman Endowed Chair in GI Oncology H Seidman Cancer Center and Case Western Reserve University Cleveland, Ohio Shubham Pant, MD Professor Department of Gastrointestinal Medical Oncology Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center Houston, Texas Link to full program:https://bit.ly/4ckcBrZ Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the current treatment landscape for frontline HER2-positive gastroesophageal junction (GEJ) and gastric cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we welcome Dr. Sunnie Kim from the University of Colorado and Dr. Samuel Cytryn from Memorial Sloan Kettering, who shared their insights on the latest advancements in HER2-targeted therapies. We discussed the pivotal TOGA and KEYNOTE-811, the promising data from the HERIZON-GEA01 study featuring Zanidatamab, and the implications of these findings for clinical practice. Key topics included: Current standard of care for HER2-positive GEJ and gastric cancer The role of PD-L1 status in treatment decisions Mechanisms and efficacy of Zanidatamab compared to traditional therapies Management of side effects, including diarrhea and infusion-related reactions Future directions in HER2-targeted therapies, including T-DXd based on the DESTINY Gastric-04 trial Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/new-precision-strategies-for-her2-gea-interpreting-new-data-to-inform-clinical-practice
Shot of Nostalgia: Shuffle continues with your host Acefield Retro, and this week we revisit April 4, 1993, WrestleMania IX from Caesars Palace in Paradise, Nevada. The first fully outdoor WrestleMania. The World's Largest Toga Party. A Roman coliseum theme complete with live animals, trumpeters, and commentators fully committed to the presentation. But beyond the spectacle, this event represents a pivot. This episode traces the road into WrestleMania IX through the March and April 1993 Wrestling Observer Newsletter coverage, capturing a company navigating lawsuits, scrutiny, roster instability, and mounting pressure. Bret Hart entered as WWF Champion. Yokozuna had been elevated as the dominant Royal Rumble winner. Hulk Hogan had returned, but his long term direction was fluid rather than locked in. The structure of the card reflects that instability. Shawn Michaels versus Tatanka opens with an Intercontinental Championship match that creates movement without definitive closure, immediately signaling protection over payoff. The Steiner Brothers versus the Headshrinkers provide one of the night's most cohesive in ring performances, reinforcing how effective the tag division could be when execution was clean. Doink versus Crush leans heavily into character psychology and spectacle, highlighted by the double Doink finish. We examine the originally planned mechanical stunt that was scrapped and what that decision says about the era's emphasis on visual moments. Razor Ramon secures a direct win over Bob Backlund, continuing his steady rise. The Tag Team Championship match between Money Inc. and the Mega Maniacs unfolds through referee bumps, disqualification tension, and spectacle driven pacing. We revisit the reported late reshuffling that removed the originally planned tag title blow off and centered Hogan more prominently on the card. Lex Luger's WrestleMania debut against Mr. Perfect introduces rope leverage controversy and is layered with behind the scenes anecdotes that contribute to the uneven rhythm of the night. The Undertaker versus Giant Gonzalez becomes one of the most criticized finishes in WrestleMania history, prioritizing theatricality over decisive resolution. The championship picture ultimately defines the event. Bret Hart versus Yokozuna is framed as a generational collision until Mr. Fuji's salt interference shifts the WWF Championship. Moments later, Hulk Hogan enters, accepts an impromptu challenge, and captures the title in approximately twenty seconds. With three decades of hindsight, this episode examines whether that closing decision reflects creative confusion or calculated business pragmatism. The Observer context suggests urgency. The optics suggest an audible. The result reshaped Bret Hart's reign, altered Yokozuna's trajectory, and placed Hogan back on top during a volatile moment for the company. WrestleMania IX is remembered for its ending. It deserves to be studied for what it reveals about transition, pressure, and how quickly direction can change when stability becomes the priority. Shot of Nostalgia: Shuffle premieres Saturday wherever you listen. Like, subscribe, and leave a review to support the continued growth of the series. Visit TurnbuckleTavern.com for merchandise, archives, and the full network schedule. Support the project at Patreon.com/TheTurnbuckleTavern for exclusive content and extended deep dives. Powered by G FUEL and Dick Lazers. Use code TAVERN at checkout to save twenty percent on your entire order.
Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02958 Timestamps · 00:00 – 02:15 Introduction and Overview · 02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma · 08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma · 10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma · 14:40 – 18:03 First-line treatment for ESCC · 18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC · 22:05 – 24:38 Importance of guideline · 24:39 – 27:45 Outstanding questions and future research Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Antonio Settembre"La toga spezzata"Viaggio nel Processo Penale e nella Riforma che cambia la Magistratura.Distribuzione: www.amazon.itUn viaggio chiaro e coinvolgente dentro i meccanismi del processo penale, per orientarsi tra regole, ruoli e recenti riforme. Scopri cosa cambia con la riforma della separazione dellecarriere e perché riguarda da vicino anche te.Durante la sua carriera, l'autore ha trattato – come relatore ed estensore della sentenza – numerosi processi importanti, tra cui la strage dei Georgofili a Firenze, del 1993, e tutte quellecollegate di via Palestro a Milano, di via Fauro a Roma, di San Giovanni in Laterano e di San Giorgio al Velabro, anch'esse commesse a Roma, oltre, ovviamente, a numerosissime altrevicende giudiziarie, soprattutto in materia fallimentare. Oggi ci racconta, attraverso la sua esperienza professionale, la complessa macchina della giurisdizione italiana, civile e penale, per arrivare a sviscerare il processo penale e comprendere i punti più cruciali del Referendum di giustizia del 22 e 23 marzo 2026."Il processo penale italiano è una delle costruzioni giuridiche più sconosciute al cittadino medio. Sebbene la sua rilevanza sociale e il suo impatto sulla vita delle persone siano estremamente significativi, la conoscenza dei meccanismi che presiedono al funzionamento del processo risulta appannaggio di pochi; in pratica, dei soli operatori giuridici - magistrati e avvocati penalisti - impegnati nella gestione dei processi.L'ambizione di questo scritto è, innanzitutto, quella di fornire, ai non addetti ai lavori, nella maniera più semplice e obbiettiva possibile, le cognizioni minime atte a comprendere qual è la struttura del procedimento penale, come nasce e come evolve e quali sono i soggetti che si muovono nell'ambito dello stesso. Ciò verrà fatto con l'utilizzo di un linguaggio non tecnico, o minimamente tecnico, per estendere al massimo la platea dei possibili fruitori di questo scritto.Non è dubitabile che la conoscenza del sistema giudiziario (riferita, quantomeno, al sistema penale) non solo aiuterà a comprendere l'evoluzione di moltissime vicende giudiziarie dell'attualità, ma può contribuire alla formazione di un giudizio più consapevole sulle infinite questioni che agitano il mondo della giustizia, squassato, come pochi altri, dalle polemiche e dalla disinformazione."Antonio Settembre nasce a Salerno nel 1955. Ha iniziato a lavorare in magistratura come pretore a Cagliari nel 1986. Successivamente, da 1991 al 1996, ha lavorato come sostitutoprocuratore a Lucca, poi giudice a Firenze dal 1996 al 2012. Fino al 2021 è stato consigliere della Corte suprema di cassazione e fino alla pensione nel 2025, Presidente di sezione della Corte d'appello di Firenze.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/
Solve crimes with the great detective in "Sherlock Holmes Short Stories." Featuring classic tales by Arthur Conan Doyle, this podcast brings you the brilliant deductions and thrilling adventures of Sherlock Holmes and Dr. Watson. Whether you're a longtime fan or new to the world of Holmes, these timeless mysteries will keep you captivated.
This episode was presented by UJA. Support UJA's work at UJA.orgSubscribe to Inside Call me Back: inside.arkmedia.org/?utm_source=shownotes&utm_medium=podcast&utm_campaign=insideGift a subscription of Inside Call me Back: inside.arkmedia.org/giftsListen to What's Your Number: lnk.to/GsOESPSubscribe to Amit Segal's newsletter ‘It's Noon in Israel':arkmedia.org/amitsegal/Watch Call me Back on YouTube: youtube.com/@CallMeBackPodcastCheck out Ark Media's other podcasts: For Heaven's Sake: https://lnk.to/rfGlrA‘What's Your Number?': https://lnk.to/rfGlrAFor sponsorship inquiries, please contact: callmeback@arkmedia.orgTo contact us, sign up for updates, and access transcripts, visit: arkmedia.org/Ark Media on Instagram: instagram.com/arkmediaorgDan on X: x.com/dansenorDan on Instagram: instagram.com/dansenorTo order Dan Senor & Saul Singer's book, The Genius of Israel: tinyurl.com/bdeyjsdnToday's Episode: We are less than a week away from the beginning of Hanukkah. Keeping with recent Call me Back tradition, Dan was joined by Rachel Goldberg-Polin to discuss the timeless meaning of the Hanukkah story. What does it say about the conflict Jews face today? Can the few really defeat the many? And why are Jews so obsessed with counting?CREDITS:ILAN BENATAR - Producer & EditorADAAM JAMES LEVIN-AREDDY - Executive ProducerBRITTANY COHEN - Production ManagerMARTIN HUERGO - Sound EditorMARIANGELES BURGOS AND PATTRICIO SPADAVECCIA - Additional EditingMAYA RACKOFF - Associate ProducerGABE SILVERSTEIN - Community ManagementYUVAL SEMO - Music Composer
We are less than a week away from the beginning of Hanukkah. Keeping with recent Call me Back tradition, Dan is joined by Rachel Goldberg-Polin to discuss the timeless meaning of the Hanukkah story. What does it say about the conflict Jews face today? Can the few really defeat the many? And why are Jews […]
Samfylkingin í Reykjavík stendur á krossgötum. Hún þarf að velja sér leiðtoga í höfuðborginni í fyrsta skipti í nærri tuttugu ár. Forsætisráðherra vill halda þar völdum og er sögð vera á höttunum eftir nýjum oddvita. Það bar til í liðinni viku, undan Senegalströndum, að ráðist var á tyrkneska olíuskipið Mersin, líklega með sprengjudrónum. Skipið er í eigu tyrknesku útgerðarinnar Besiktas shipping en siglir undir fána Panama - og er talið tilheyra hinum svokallaða skuggaflota Rússa. Úkraínumenn hafa ekki gengist við árásinni en árásum af þessu tagi hefur fjölgað og þær eru taldar á gráu svæði. Á miðvikudaginn (10. desember) tekur bann við samfélagsmiðlanotkun barna undir sextán ára gildi í Ástralíu og varðar háum sektum ef fyrirtæki ganga ekki fram í að koma í veg fyrir að ungmenni komist á miðlana.
If movies like Animal House, Legally Blonde, and The House Bunny shaped your Greek life dreams… brace yourself. Greek life isn’t what Hollywood promises.See omnystudio.com/listener for privacy information.
Two Jersey Js with Jackie Goldschneider and Jennifer Fessler
If movies like Animal House, Legally Blonde, and The House Bunny shaped your Greek life dreams… brace yourself. Greek life isn’t what Hollywood promises.See omnystudio.com/listener for privacy information.
Nur ein Anno mit Toga? Wir diskutieren die historische Korrektheit von Anno 117: Pax Romana mit Micha, der Archäologin Michaela Zietlow und Strategie-Experten Gaius. Logistik, Kultur und das finale GameStar-Urteil!
Bogi Ágústsson og Þórunn Elísabet Bogadóttir ræddu fundahöld evrópskra leiðtoga í Kaupmannahöfn um fjölþáttaógnina frá Rússum. Leiðtogar Evrópusambandsins þinguðu í gær og í dag bætast fleiri evrópskir leiðtogar í hópinn, þar á meðal Kristrún Frostadóttir forsætisráðherra Íslands. Þá var einnig rætt um úrslit kosninga í Moldóvu þar sem PAS-flokkurinn (Aðgerðir og samstaða), fékk meirihluta þingsæta. PAS vill náið samstarf við Vesturlönd og inngöngu í Evrópusambandið.
We're wrapping up 1 & 2 Peter with quizzes written by our listeners!If you want MORE drinking and bible-ing, including bonus episodes, interviews with experts, fun mini series', and more, consider becoming a ‘parishioner' at Patreon.com/DrunkBibleStudyOur theme music is Book Club by Josh and Anand.
© 2020-2026 Ivy Podcast Discovery LLC
